Clinical trials
catalyst calendar across sponsors →Studies where ARVN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 1 with posted results
Held by 14 tracked-famous managers (D. E. Shaw & Co., Inc., TWO SIGMA INVESTMENTS, LP, Qube Research & Technologies Ltd, CITADEL ADVISORS LLC, AQR CAPITAL MANAGEMENT LLC, +9 more) · FINRA short interest 7.0 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 2 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsNCT07749586Part A1: Number of Dose-Limiting Toxicities (DLTs) of ARV-6723Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: ARV-6723, Pembrolizumab, SOC | Advanced Solid Tumor | 499 | 2031-03-31 | in 1,684 d | 2026-08-06 |
| A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.NCT06393738Incidence of Dose Limiting Toxicities During First 28 DaysOpen-label · Treatment | Phase 1 | Recruiting | Drug: ARV-393, Glofitamab | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL) | 255 | Mar 2028 | ≤ 589 d | 2026-02-10 |
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D MutationNCT07023731Part A (Phase 1): Number of dose-limiting toxicities (DLTs) of ARV-806Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: ARV-806 | KRAS G12D Mutation, Advanced Solid Cancer | 159 | 2026-11-30 | in 102 d | 2026-08-19 |
| A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to SurgeryNCT05549505results2025-08-29Percent Reduction in Ki-67 Expression From Baseline to Day 15 in Tumor BiopsiesRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ARV-471, Anastrozole · Procedure: Surgical resection of breast tumor | Breast Cancer | 152 | 2024-07-13actual | — | 2025-08-29 |
| Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate CancerNCT03888612Part A: Incidence of Dose Limiting Toxicities of ARV-110Open-label · Treatment | Phase 1/2 | Completed | Drug: ARV-110 | Prostate Cancer Metastatic | 248 | 2024-04-29actual | — | 2025-04-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19